Nutriband Inc. (NTRB) Stock Score, Valuation & Financial Research
Nutriband Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 20/100.
Quick answer for NTRB
Nutriband Inc. currently has a Wall Street Score of 20/100. The stored market price is $6.93. Its financial score is 25/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Nutriband Inc. does
Nutriband Inc. specializes in developing a diverse range of pharmaceutical products delivered via transdermal patches. The company's most advanced program centers on AVERSA fentanyl, an innovative fentanyl transdermal system engineered to prevent abuse. This extended-release patch provides healthcare professionals and patients with a continuous opioid therapy solution for the ongoing management of chronic pain. Its development pipeline also includes other treatments, such as AVERSA buprenorphine and AVERSA methylphenidate. Additionally, Nutriband is working on exenatide for individuals with type 2 diabetes and follicle stimulating hormone as a treatment for infertility. The company also holds a licensing agreement with Rambam Med-Tech Ltd. to further the development of RAMBAM Closed System Transfer Devices. Nutriband Inc. was founded in 2016 and its main offices are located in Orlando, F
NTRB financial snapshot
- Wall Street Score:
- 20/100
- Current price:
- $6.93
- Market capitalization:
- $84.2M
- Revenue:
- $1.8M
- Net income:
- $-8.1M
- Free cash flow:
- $-5.1M
- Cash:
- $4.0M
- Total debt:
- $233K
- EPS:
- -2.58
- Financial score:
- 25/100
- Valuation score:
- 0/100
- Revenue score:
- 1/100
What stands out
- Reported year-over-year revenue growth is -0.1%.
- Free cash flow is $-5.1M, showing cash burn in the current stored period.
- The balance sheet shows $4.0M of cash versus $233K of total debt, leaving more cash than debt.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 25/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research NTRB
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.